Screening for Aortic Aneurysms in Inland Norway
Launched by SYKEHUSET INNLANDET HF · May 3, 2024
Trial Information
Current as of June 26, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
Abdominal aortic aneurysm (AAA) is a dilatation of the main artery from the heart as it passes through the abdomen. In case of rupture, the condition is life threatening and acute surgery is required. The prevalence of AAA is four to six times higher in men as compared to women, and varies greatly between countries and regions, but is generally reported to be present in 1.5-5% of men. Over the last three decades, the prevalence of AAA has been relatively stable, despite improved medical therapy for cardiovascular disease and a declining use of tobacco in Norway and comparable countries. Thi...
Gender
MALE
Eligibility criteria
- Inclusion Criteria:
- • All men in Inland Norway are invited
- Exclusion Criteria:
- • unwilling or unable to concent
About Sykehuset Innlandet Hf
Sykehuset Innlandet HF is a prominent healthcare provider in Norway, dedicated to delivering high-quality medical services and advancing clinical research. As a key player in the region's healthcare landscape, the organization operates several hospitals and specialized units, focusing on a wide range of medical disciplines. Sykehuset Innlandet HF is committed to fostering innovative clinical trials that enhance patient care and contribute to the development of new therapies. With a strong emphasis on collaboration and ethical standards, the organization seeks to improve health outcomes through rigorous research and evidence-based practices.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Hamar, , Norway
Patients applied
Trial Officials
Simen T Berge, MD PhD
Study Chair
Sykehuset Innlandet, UiO
Chrissie M Andersen, MD
Principal Investigator
Sykehuset Innlandet, UiO
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported